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Summary
Targeted therapy has been the standard of care for the treatment of metastatic renal cell carcinoma (mRCC). The 
 current standard of care focuses on tyrosine kinase inhibitors (sunitinib, sorafenib, pazopanib, axitinib), antibodies to circu-
lating VEGF receptor (bevacizumab) and m-TOR inhibitors (temsirolimus, everolimus). New immune-based therapies are 
emerging as a promising treatment for mRCC. Immune checkpoint blockade has shown clinically signifi cant antitumor re-
sponse. Monoclonal antibodies against immune checkpoint blockade molecules including PD-1 (programmed cell death 1) 
and CTLA-4 (cytotoxic T lymphocyte antigen 4) have become a major focus in the immune-based therapy since it has been 
reported that they have impressive antitumor eﬀ ects.
The most studied inhibitors in the PD-1 pathway are: nivolumab, pembrolizumab and atezolizumab. Based on the 
results of the phase III clinical trial (CheckMate025) nivolumab, humanized monoclonal IgG4 antibody against PD-1, is the 
only agent that is approved by the FDA for the second-line treatment of mRCC. Ipilimumab is the fi rst-in-class immuno-
therapeutic for blockade of CTLA-4. The immunotherapy combinations have demonstrated promising results in a random-
ized trials. The use of cancer treatment vaccines is another approach to immunotherapy and will be systematically evalu-
ated in the future.
Immunotherapy has demonstrated great clinical potential and it represents crucial component of mRCC treatment. 
Developing immunotherapy to the point of clinical utility presents a number of issue and challenges, and more rigorous 
studies are needed.
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IMUNOTERAPIJA KARCINOMA BUBREGA
Sažetak
Ciljana terapija danas predstavlja osnovicu sistemskog liječenja metastatskog raka bubrega (mRB), a standard liječenja 
su tirozin-kinazni inhibitori (sunitinib, sorafenib, pazopanib, aksitinib), protutijela na cirkulirajući VEGF receptor (beva-
cizumab) i m-TOR inhibitori (temsirolimus, everolimus). Noviji imunoterapijski principi predstavljaju značajne iskorake u 
liječenju mRB. Jedna forma imunoterapije je inhibicija imunoloških kontrolnih točaka (eng. immune checkpoint). Blo-
kiranjem jednog od dva najistraživanija imunološka receptora; antigen 4 povezan s aktivnošću citotoksičnih T-limfocita 
(CTLA-4) i receptor programirane stanične smrti (PD-1), potenciramo antitumorski imunološki odgovor.
Među najistraživanije anti-PD-1 inhibitore ubrajamo: nivolumab, pembrolizumab i avelumab. Nivolumab je ljudsko 
monoklonalno antitijelo kojega je Američka agencija za hranu i lijekove odobrila u drugoj liniji liječenje mRB, a na osnovi 
rezultata kliničke studije faze III (CheckMate025). Ipilimumab je prvi registrirani checkpoint inhibitor koji blokira inhibi-
torni signal (CTLA-4 receptor) na površini citotoksičnih T limfocita. Veliki pomak u imunoterapiji mRB postigut je primje-
nom konkomitantnih protokola liječenja. Novija istraživanja primjene imunoterapije u liječenju raka bubrega uključuju i 
pronalaženje cjepiva koje bi prepoznavalo i uništavalo promijenjene tumorske stanice.
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Imunoterapija ima jasno mjesto i veliki potencijal u liječenju raka bubrega. Ipak, postoji još niz problema i pitanja te su 
potrebna brojna daljnja istraživanja kako bi se iskoristio njen puni potencijal.
KLJUČNE RIJEČI: karcinom bubrega, imunoterapija, inhibicija imunoloških kontrolnih točaka, cjepiva.
INTRODUCTION
Worldwide, the incidence of renal cell carci-
noma (RCC) has steadily increased over the last 
two decades. In 2014 the Croatian National Can-
cer Registry stated 731 new cases of RCC diag-
nosed in Croatia (1). About one quarter of patients 
will present with metastatic disease at the time of 
diagnosis, and another quarter will develop meta-
static disease despite complete surgical removal of 
the primary tumor (2). Clear cell RCC is the most 
prevalent histologic subtype being assigned to 
70–80% of all RCC patients (2).
Advanced and metastatic RCC (mRCC) is 
highly lethal tumor with a poor prognosis. Since 
RCC is highly resistant to chemotherapy, three 
major categories of systemic drugs are currently 
being used as fi rst-line treatment of metastatic dis-
ease: drugs that target the vascular endothelial 
growth factor (VEGF) pathway (inhibitors of tyro-
sine kinase - sunitinib, sorafenib, pazopanib, ax-
itinib, tivozanib cabozantinib; the monoclonal an-
tibody against VEGF receptor - bevacizumab), 
drugs that target the mTOR pathway (mTOR in-
hibitors - temsirolimus, everolimus) and immune-
based therapies (3).
IMMUNOTHERAPY
Renal cell carcinoma represents an immuno-
sensitive tumor due to high levels of tumor infi l-
trating immune cells, including lymphocytes, 
macrophages and dendritic cells (2). Multiple dif-
ferent mechanisms of immunosuppression are 
preventing immune cells from exercising their an-
titumor activities. These mechanisms are being 
intensively investigated in hope of fi nding thera-
peutically safe and eﬀ ective inhibitors able to 
counteract tumor-induced immunosuppression.
More than two decades, unspecifi c immuno-
therapy using cytokines, interleukin-2 (IL-2) and 
interferon-α (IFNα), had been the mainstay for 
management of advanced disease.
IFNα as the fi rst biologics to be evaluated in 
the mRCC sett ing (4). It has anti-proliferative and 
immune stimulatory activity. On the other hand it 
is a diﬃ  cult drug to use because of the chronic ad-
ministration as well as the severity and chronicity 
of side eﬀ ects and it is inferior to most of the new-
er agents. Based on the results of several phase III 
trials, which suggest that greatest therapeutic po-
tential of IFNα may be realized in combination 
with other biological response modifi ers, it is cur-
rently approved as a treatment for patients with 
mRCC in combination with bevacizumab (5,6).
High-dose bolus IL-2 (HD IL-2) was ap-
proved by the Food and Drug Administration 
(FDA) in 1992 for the treatment of mRCC due to 
the potential for durable complete responses (7%) 
in a small number of patients, but the toxicity of 
HD IL-2 therapy, in particular, make it a poor 
standard therapy (7). Despite many limitations, 
this treatment modality remains valuable thera-
peutic option for eligible patients and should be 
considered in the treatment algorithm at centers 
with adequate experience.
Although many factors have limited its gen-
eralized use, the succes of its application serves us 
as proof of principle that immunotherapies can 
eliminate tumor cells in some patients, encourag-
ing eﬀ orts to develop bett er tolerated and more 
eﬀ ective immunotherapy regimens.
CHECKPOINT INHIBITION
Numerous studies have begun to discover 
the multiple mechanisms by which renal cancer 
cells can avoid being att acked by the immune sys-
tem, and recently, monoclonal antibodies against 
immune checkpoint blockade molecules includ-
ing PD-1 (programmed cell death 1) and CTLA-4 
(cytotoxic T lymphocyte antigen 4) have become a 
major focus in the immune-based therapy (8).
Programmed cell death 1 molecule is ex-
pressed on the surface of activated T cells, and 
 interaction between PD-1 and its ligands, pro-
grammed death-ligand 1 (PD-L1) and program-
med death-ligand 2 (PD-L2), leads to T cell inacti-
vation. Anti-PD-1 antibodies (nivolumab, pem-
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brolizumab, atezolizumab and avelumab) can 
bind to the PD-1 receptor, blocking its interaction 
with PD-L1/L2 to prevent T cell inactivation (9).
In the randomized, open-label, phase III con-
trolled trial (CheckMate025), nivolumab (a mono-
clonal IgG4 antibody against PD-1) was compared 
with everolimus in patients with mRCC who re-
ceived prior treatment (10). The study demon-
strated an overall survival (OS) benefi t of nivolum-
ab compared with everolimus (25.0 months versus 
19.6 months) following progression on fi rst-line 
treatment (inhibitors of tyrosine kinase). Safety 
analyses showed that 19% of the patients receiv-
ing nivolumab experienced grade 3/4 treatment-
related adverse events (AE) versus 37% for those 
receiving everolimus. The most common AE expe-
rienced by patients in the nivolumab group was 
fatigue (in 2% of the patients). Based on that, in 
2015, the FDA approved nivolumab for advanced 
RCC in the second-line sett ing. Following this ap-
proval, various anti-PD-1 antibodies are actively 
being investigated for use in mRCC (11,12,13).
Early studies (CheckMate016, CheckMate214) 
suggest that combination therapy of checkpoint 
inhibitors with targeted therapy, even combina-
tion therapy of dual immune checkpoint inhibi-
tion (CTLA-4 plus PD-1) may potentially provide 
additional clinical benefi t not seen with either mo-
dality alone (14,15).
Fully humanized, engineered monoclonal 
antibody against PD-L1 protein, atezolizumab, 
was initially approved for the treatment of pa-
tients with advanced urothelial cancer (16). In a 
global, multicentre, open-label, randomised phase 
II study (IMmotion150) 305 patients with previ-
ously untreated, locally advanced or mRCC were 
randomly assigned to atezolizumab plus bevaci-
zumab, atezolizumab alone or sunitinib alone. An 
analysis of results found that patients whose can-
cer expressed PD-L1 and were treated with at-
ezolizumab plus bevacizumab had improvement 
in progression-free survival (PFS) compared to 
those who were treated with sunitinib alone (14.7 
vs 7.8 months) (17). Frequency of all-grade treat-
ment-related AE were similar between arms. The 
results from ongoing phase III study (IMmo-
tion151) will help to confi rm clinical benefi t of 
combined therapy with atezolizumab and bevaci-
zumab in patients with RCC (18).
Ipilimumab, a fully humanized anti-CTLA-4 
antibody, is approved by the FDA for the treat-
ment of advanced melanoma (19). It has been in-
vestigated in combination with nivolumab in 
mRCC (the nivolumab–ipilimumab arm of Check-
Mate016) (20). Full doses of nivolumab and ipi-
limumab were not tolerated, but nivolumab with 
reduced dose ipilimumab was reasonably well tol-
erated. These should be further evaluated, partic-
ularly in the context of dose and schedule modifi -
cation and combination therapy.
The CheckMate214 study compares the com-
bination of nivolumab plus ipilimumab to suni-
tinib monotherapy in patients with previously un-
treated mRCC. The study will provide valuable 
information on the optimal initial treatment ap-
proach for patients with all-risk groupings of 
mRCC. Further trials investigating ipilimumab 
alone and in combination with other drugs are on-
going (21,22).
Based on their mechanism of action, check-
point inhibitors are associated with select AE, tox-
icities that have an autoimmune etiology and re-
quire specifi c management strategies. The most 
common and typically earliest onset adverse reac-
tion include dermatologic toxicity in the form of 
rash and pruritus, gastrointestinal AE in the form 
of diarrhea and colitis, hepatotoxicity, endocri-
nopathy in the form of hypophysitis and hypothy-
roidism, pneumonitis and renal insuﬃ  ciency (23). 
Treatment-related immune AE are predominantly 
grade 1 or 2 in severity, and can be managed by 
holding or discontinuing the checkpoint inhibi-
tors and administering high-dose corticosteroids 
followed by other immune modulatory agents if 
side eﬀ ects are not quickly controlled (24). If iden-
tifi ed early, they are almost always reversible, but 
if they go unrecognized, these events can lead to 
signifi cant morbidity, even death. Compared to 
drugs that target PD-1, serious AE seem to be 
more likely with antibody against CTLA-4.
VACCINES
The use of cancer treatment vaccines is an-
other approach to immunotherapy. The role of 
vaccine target antigens, target delivery and im-
mune stimulants will have to be systematically 
evaluated in the future. In contrast to other cyto-
toxic therapies, cancer vaccines have demonstrat-
ed minimal toxicity in all clinical trials that have 
been reported to date.
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The clinical translation of cancer vaccines 
into eﬃ  cacious therapies has been challenging for 
several decades with mixed results. In April 2010, 
the FDA approved the fi rst therapeutic cancer vac-
cine, sipuleucel-T, an autologous immune cell 
prostate cancer vaccine (25).
Due to recent advances in research, therapeu-
tic vaccines are steadily gaining ground as prom-
ising treatment modalitie against RCC, especially 
when they are given in combination with other 
forms of cancer therapy (26).
The multipeptide vaccine IMA901, based on 
9 tumor-associated peptides, has recently been as-
sessed in a phase III clinical trial. In this trial, pa-
tients with mRCC were randomized to receive ei-
ther sunitinib with IMA901 or sunitinib alone as 
fi rst-line treatment (27). The study demonstrate 
no survival advantage to the addition of IMA901 
to sunitinib versus sunitinib alone, while the ran-
domized phase II trial demonstrated a clear asso-
ciation of a clinical benefi t in mRCC patients with 
an immunological response to the administered 
synthetic tumor-associated peptide (28).
Dendritic cell-based vaccine (AGS-003) for 
RCC is being investigated in combination with 
well-established targeted drug therapies (suni-
tinib) in a clinical trial phase III (ADAPT) (29).
Early results showed that the combination of 
AGS-003 and sunitinib can potentially maximize 
immune response in patients, with a goal of add-
ing litt le to no toxicity (30). Further studies allow-
ing for assessment of survival advantage related 
to AGS-003 are anticipated. However, the true 
benefi t for cancer vaccines may be in the adjuvant 
sett ing.
CONCLUSION
Signifi cant increase in the understanding of 
the biology of RCC has resulted in notable achie-
vements in treatment options. Complete and 
 durable unmaintained remissions are rare with 
agents that target VEGF or mTOR pathway, which 
diﬀ ers from the small percentage of patients 
reaching complete remissions with high-dose IL-
2-based immunotherapy.
A new class of immunotherapy agents, im-
mune checkpoint inhibitors, has ushered in a new 
era in the treatment of patients with mRCC. Early 
results from some current trials are extremely en-
couraging and will likely lead to more indications 
in addition to the approved indications for the 
treatment of mRCC. While the eﬃ  cacy of these 
new therapies is enhanced, the toxicity is less se-
vere than that seen with other treatment moda-
lities. The toxicities from checkpoint immuno-
therapy represent a new class of adverse events, 
manageable with early application of systemic 
corticosteroids or immunomodulators.
Therapeutic cancer vaccines of diﬀ erent 
forms are being actively evaluated in the clinic. A 
bett er understanding of host-tumor interactions 
and tumor immune escape mechanisms are re-
quired to develop eﬀ ective cancer vaccines.
Optimal sequencing, investigating biomark-
ers and other factors predictive of response and 
resistance to immunotherapy and evaluating the 
combination of diﬀ erent treatment modalities 
(immunotherapy with targeted therapy, or multi-
ple immune-modulators) become even more im-
portant in order to select patients with the greatest 
chance of durable disease control and survival.
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